These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9736576)

  • 1. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.
    Zhanel GG; Kirkpatrick ID; Hoban DJ; Kabani AM; Karlowsky JA
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2427-30. PubMed ID: 9736576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Houlihan HH; Rybak MJ
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
    al-Nawas B; Shah PM
    Infection; 1998; 26(3):165-7. PubMed ID: 9646108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
    Jones RN; Barrett MS; Erwin ME
    Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
    Baltch AL; Smith RP; Ritz WJ; Bopp LH
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
    Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
    Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
    Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
    Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP; Andrews J; Wise R
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of human albumin on bactericidal or antibacterial activities of cephems and monobactams].
    Saionji K
    Jpn J Antibiot; 1988 Oct; 41(10):1390-406. PubMed ID: 3144613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma protein binding of fluoroquinolones affects antimicrobial activity.
    Zeitlinger M; Sauermann R; Fille M; Hausdorfer J; Leitner I; Müller M
    J Antimicrob Chemother; 2008 Mar; 61(3):561-7. PubMed ID: 18216178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of different pathophysiological conditions on antimicrobial activity of glycopeptides in vitro.
    Oesterreicher Z; Eberl S; Nussbaumer-Proell A; Peilensteiner T; Zeitlinger M
    Clin Microbiol Infect; 2019 Jun; 25(6):759.e1-759.e7. PubMed ID: 30267931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.
    Zeckel ML; Preston DA; Allen BS
    Antimicrob Agents Chemother; 2000 May; 44(5):1370-4. PubMed ID: 10770782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of oritavancin serum protein binding across species.
    Arhin FF; Belley A; McKay G; Beaulieu S; Sarmiento I; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3481-3. PubMed ID: 20498314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
    Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.